Published in Vaccine Weekly, October 12th, 2005
The drug is being developed in collaboration with Merck KGaA of Darmstadt, Germany.
The phase II trial will assess the safety of the formulation of L-BLP25 that the Companies plan to use in the upcoming phase III study. The phase III trial design is currently being discussed with the U.S. Food and Drug Administration.
The formulation incorporates manufacturing changes intended to secure the future commercial supply of the vaccine. Initial results from the 20-patient trial...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.